Neurodegenerative diseases affect about 15 % of the global population and are on the rise due to aging demographics. Neuroinflammation, driven by the brain’s immune cells known as microglia, is a key factor in these diseases.
Due to microglia’s close link to neurodegenerative diseases like Alzheimer's, ALS, and Parkinson’s, they play an increasingly vital role in in vitro neurodegenerative and neurological disease modeling.
Human iPSC-derived microglia retain the donor's phenotypic characteristics, making them ideal for creating human-relevant model systems. These microglia offer exciting opportunities to test potential therapies in disease-specific models, advancing research and drug discovery.
Discover how iPSC-derived microglia is helping advance neuroinflammation research and disease modeling.
Download the Brochure for More Information
eBook highlights
- Overview of iPSC-derived microglia characterization, methods to asses functional relevance, and strategies to ensure quality control
- Insights into how
- A look at how Axol Bioscience conducts its custom lab techniques, such as compound screening, to leverage microglia projects
- Axol’s method for microglia bulk manufacturing and how to achieve excellent functional consistency
This microglia eBook by Axol Bioscience offers valuable insights on overcoming technical challenges, advancing therapy development for patients worldwide, and unlocking the full potential of iPSC technology for your microglia projects.
Download the eBook
About AXOL Biosciences
Axol specializes in human cell culture.
Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.
Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.
The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.